FDA uncovers additional types of cancer possibly linked to breast implants ESMO: GSK keeps the faith in anti-TIGIT plans; it's 'not always about being first' Envision Healthcare sues UnitedHealth over claim denials ESMO: AstraZeneca, Merck tout Lynparza's 'clinically meaningful' ovarian cancer survival edge but lose one in prostate cancer RADx reloaded: NIH puts out the call for more effective, easier-to-use COVID tests ESMO: Adding bempeg to Opdivo lowered response rate in Bristol Myers-Nektar failed cancer trial COVID vaccine coverage questions abound for health insurers Arcutis' psoriasis cream Zoryve clinches win in seborrheic dermatitis trial, proving it's no one trick pony in itch After flunking studies last year, Allakos’ failed phase 3 EoDyssey sinks gastrointestinal program Baxter infusion pumps found to be at risk of remote hacking After 'watershed' approval, Takeda nears dengue vaccine launch and gears up for more green lights Backup generators fail at Northern California hospital during record-breaking heat wave Featured Story | By Conor Hale The FDA has found new clusters of specific types of cancer linked to the scar tissue that forms around breast implants, as part of its ongoing, years-long review of the risks that can come with the procedure. read more |
| |
|---|
|
Top Stories By Max Bayer Four months after the latest trial failure for Roche’s tiragolumab, GSK is still pushing ahead with its own anti-TIGIT inhibitor, bullish that plenty of opportunities remain for the next-gen therapy. read more By Paige Minemyer UnitedHealthcare's war with physician staffing firms continues. Envision Healthcare filed suit against the insurer, the physician firm announced Friday, over claim denied by the country's largest health plan. read more By Angus Liu In a heated PARP inhibitor race with GSK, AstraZeneca and Merck hope some new survival data could consolidate Lynparza’s lead in an ovarian cancer subset. But Merck can’t say the same about a potential prostate cancer expansion. read more By Andrea Park RADx is offering a total of $300 million in funding from the 2021 American Rescue Plan Act to help support not only the development of the next wave of future COVID-19 tests but also their regulatory aspirations—including both pandemic-induced emergency use authorization and full market clearance. read more By Nick Paul Taylor The European Society for Medical Oncology (ESMO) congress could have been a victory lap for Bristol Myers Squibb and Nektar Therapeutics, the moment when a bold bet delivered clinical data to upend the immuno-oncology space. Instead, the partners were left to sift through the wreckage of a failed trial that suggested bempegaldesleukin may make Opdivo less—not more—effective. read more By Frank Diamond Health plans in the near future will have to start covering COVID-19 vaccines and tests that up until now had been “free.” Free is a tough act to follow. read more By Fraiser Kansteiner Friday at the European Academy of Dermatology and Venereology 2022 congress, Arcutis drew the curtain back on late-stage Zoryve data in seborrheic dermatitis—a chronic inflammatory skin disease where the company is testing its drug in adults and kids ages nine years and up who have moderate-to-severe disease. read more By Nick Paul Taylor Allakos has achieved an undesired hat trick. Across three phase 3 trials, the biotech has now significantly reduced levels of a troublesome white blood cell without improving symptoms, driving it to rethink the development of an anti-Siglec-8 antibody that was once among the hottest prospects in biotech. read more By Andrea Park Baxter’s infusion pumps are in the crosshairs once again after cybersecurity software developer Rapid7 discovered multiple potential vulnerabilities in the devices. read more By Zoey Becker It's been a long journey for Takeda's dengue fever vaccine, which recently won its first global approval in Indonesia. After Sanofi's dengue vaccine disaster, the company had to learn from a peer's troubles for its own development work. read more By Dave Muoio Emergency plans kicked into effect when parts of Santa Clara Valley Medical Center were became completely powerless for roughly four hours. Despite transfers and discharges, no patients were put into life-threatening situations, the system said. read more Resources Sponsored by: Genpact Learn how a private health insurance company uses analytics to deliver exceptional service to its employees and members Sponsored by: ReachBio | The Cell Biology Experts™ How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation Sponsored by: DocuSign Today’s healthcare systems are adapting to an ever changing landscape with declining margins, M&A pressures, and the need for staff flexibility due to shortages. Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens. Sponsored by: Blue Matter, strategic consultants in the life sciences This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series). Sponsored by: Ferma.AI, a Product of ZoomRx Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Catalent Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Bio-Techne Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella. Sponsored by: Thermo Fisher Scientific Set a solid foundation for successful scale-up of buffer preparation. Sponsored by: JLL Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. |
